For patients with HER2+ early breast cancer with ≥cT2 or those with nodal disease (cN+), the standard of care is neoadjuvant therapy with trastuzumab + pertuzumab + chemotherapy (strong recommendation). This evidence concerns the gene ERBB2 and breast carcinoma.